Sygnature Discovery

SEPTEMBER 12, 2024

Fragment Based Drug Discovery Crystallographic fragment screening using a high solubility curated fragment library devoid of soluble aggregates. Curated covalent fragment library also available. Fragment analogs identified for rapid follow-up. PANDDA analysis for rapid delivery of a hit list.

Fragment Screening 52

Fragment Screening RNA Protein Production DNA 52

Drug Target Review

NOVEMBER 1, 2023

We support the drug discovery projects of the CCDD with assay development and screening, biophysics, structural biology and recombinant protein production. With all these diverse methods we characterise protein-ligand interactions in many ways. We can screen with many different formats and modalities.

Fragment Screening 96

Fragment Screening Biochemical Assays Small Molecule Biophysical Assays 96

Sygnature Discovery

APRIL 26, 2022

Sygnature have acquired Peak Proteins Ltd. Following an extensive partnership between the two companies, this deal will enable seamless integration of protein production and related structure determination projects within Sygnature. The Peak Proteins leadership team will also remain with the business.

Fragment Screening 52

Fragment Screening Protein Production Protein Expression Production 52